There were 640 press releases posted in the last 24 hours and 151,485 in the last 365 days.

Musculoskeletal Now Offers The Best Opportunities to Pharma Investors, Says TBRC

Leading Global Pharma Segments In 2017

Leading Global Pharma Segments In 2017

LONDON, GREATER LONDON, UK, April 17, 2018 / -- By 2021, the market for drugs to treat conditions like arthritis and osteoporosis will be the largest global pharma segment, worth $177 billion a year, a report from The Business Research company shows. That compares with cancer drugs, which will be worth $165 billion in 2021 and cardiovascular at $141 billion.

The explanation lies with the different drug market growth rates from 2017 to 2021 - global musculoskeletal drug sales will increase at 8% year on year, those for cancer at 7% and for heart-related disease at a mere 2.2%.

The fastest-growing pharma segment will be that for metabolic disorders (to treat conditions such as diabetes and disorders of the thyroid and pituitary gland) but this will still in 2021 be in fifth place for market size behind the musculoskeletal, oncology, cardiovascular and anti-infective drug markets.
The pharma market as a whole was worth $934.5 billion in 2017 and will reach $1170 billion in 2021, growing at 5.8%, an accelerated pace compared to 5.2% for the years before 2017.

North America (the USA, Canada and Mexico) will continue to be the largest regional markets for the pharma companies, worth $341 billion a year, with Asia Pacific in next place with $200.8 billion of annual sales. Growth has been and will continue to be spread across all regions of the world, though faster in some than others. North America's growth will be only 5.1% a year, below the global average, while Asia Pacific's will be the highest globally at 8.4% per annum. Western Europe is expected to have the lowest annual growth rate of 3.9% from 2017 to 2021. Its share in the global market in 2017 was 19.4%, worth $180.9 billion.

Rising GDP per capita making drugs and treatment more affordable in the emerging regions like Asia Pacific and population ageing leading to higher incidence of chronic disease in the developed regions are the primary factors leading to the growth of pharma markets.

The pharmaceutical drugs industry includes establishments that develop drugs to diagnose, cure, treat or prevent metabolic diseases. Pharmaceutical companies produce both generic and branded drugs. Pharmaceutical drugs are subject to a number of laws and regulations that deal with patenting, testing, safety, efficacy and marketing and affect the size and growth rates of the market. Pharmaceutical companies produce pharmaceutical drugs made from active pharmaceutical ingredients (API) and excipients.

The leading pharma companies are Swiss company Novartis, with just under 5% of the global market in 2017, followed by Sanofi, which is French, then Hoffmann-La Roche, Swiss again. The top ten pharmaceutical manufacturers shared a little over 30% of the global market between them.

Where to Learn More
Read the Pharmaceutical Drugs Market Report from The Business Research Company for information on the following:
Markets Covered: Musculoskeletal Disorder Drugs, Cardiovascular Drugs, Oncology Drugs, Anti-infective Drugs, Metabolic Disorder Drugs, Central Nervous System Drugs, Genito-urinary Drugs, Gastrointestinal Drugs, Hematology Drugs, Dermatology Drugs, Ophthalmology Drugs, Drugs For Respiratory Diseases.
Pharmaceutical Companies Mentioned: Novartis AG, Sanofi S.A., F. Hoffman-La Roche Ltd., Pfizer Inc. and Gilead Sciences Inc.
Countries: India, China, Japan, Australia, UK, Germany, France, Italy, Spain, Russia, USA, Brazil
Regions: North America, South America, Western Europe, Eastern Europe, Africa, Middle East, Asia Pacific
Time Series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, population, GDP, Pharmaceutical Drugs Indicators Comparison.
Data Segmentations: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report are sourced using endnotes.

Oliver Guirdham
The Business Research Company
+44 207 1930 708
email us here